Aims An improved left ventricular ejection fraction (HFiEF) was observed across heart failure (HF) patients with a reduced or mid‐range ejection fraction (HFrEF or HFmrEF, respectively). We postulated that HFiEF patients are clinically distinct from non‐HFiEF patients. Methods and results A total of 447 patients hospitalized due to a clinical diagnosis of HF (LVEF <50% at baseline) were enrolled from September 2017 to September 2019. Echocardiogram re‐evaluation was conducted repeatedly over 6 months of follow‐up after discharge. The primary endpoint included the composite of HF hospitalization and all‐cause mortality. Subjects (n = 184) with HFiEF (defined as an absolute LVEF improvement≥10%) were compared with 263 non‐HFiEF (defined by <10% improvement in LVEF) subjects. Multivariable Cox regression was performed and identified younger age, smaller left ventricular end diastolic dimension (LVEDD), beta‐blocker use, AF ablation and cardiac resynchronization therapy (CRT) as independent predictors of HFiEF. According to Kaplan–Meier analysis, HFiEF subjects had lower cardiac composite outcomes (P = 0.002) and all‐cause mortality (P = 0.003) than non‐HFiEF subjects. Multivariate Cox survival analysis revealed that non‐HFiEF (compared with HFiEF) was an independent predictor of both the primary endpoints (HR = 0.679, 95% CI: 0.451–0.907, P = 0.012), which was driven by all‐cause mortality (HR = 0.504, 95% CI: 0.256–0.991, P = 0.047). Conclusions These data confirm that compared with non‐HFiEF, HFiEF is a distinct HF phenotype with favourable clinical outcomes.
22 April 2025 in Reviews in Cardiovascular Medicine
Congenital long QT syndrome (LQTS) is a potentially life-threatening hereditary arrhythmia characterized by a prolonged QT interval on electrocardiogram (ECG) due to delayed ventricular repolarization. This condition predisposes individuals to severe arrhythmic events, including ventricular tachycardia and sudden cardiac death. Traditional approaches to LQTS research and treatment are limited by an incomplete understanding of its gene-specific pathophysiology, variable clinical presentation, and the challenges associated with developing effective, personalized therapies. Recent advances in human induced pluripotent stem cell (iPSC) technology have opened new avenues for elucidating LQTS mechanisms and testing therapeutic strategies. By generating cardiomyocytes from patient-specific iPSCs (iPSC-CMs), it is now possible to recreate the patient’s genetic context and study LQTS in a controlled environment. This comprehensive review describes how iPSC technology deepens our understanding of LQTS and accelerates the development of tailored treatments, as well as ongoing challenges such as incomplete cell maturation and cellular heterogeneity.
Ibutilide is commonly used for conversion of atrial fibrillation (AF) during catheter ablation procedure. Sinus arrest or Torsades de Pointes (TdP) is mainly complication of ibutilide, however, is recovery spontaneously after a few hours.We present a patient suffering long persistent sinus arrest and Torsades de pointes following administration of ibutilide for cardioversion of persistent AF after radiofrequency ablation.
Background There is a lack of tools specifically designed to assess mortality risk in patients with atrial fibrillation (AF). The aim of this study was to utilize machine learning methods for identifying pertinent variables and developing an easily applicable prognostic score to predict 1-year mortality in AF patients. Methods This single-center retrospective cohort study based on the Medical Information Mart for Intensive Care-IV (MIMIC-IV) database focused on patients aged 18 years and older with AF. The study thoroughly scrutinized patient data to identify and analyze variables, encompassing demographic variables, comorbidities, scores, vital signs, laboratory test results, and medication usage. The variable importance from XGBoost guided the development of a logistic model, forming the basis for an AF scoring model. Decision curve analysis was used to compare the AF score with other scores. Python and R software were used for data analysis. Results A cohort of 59,595 AF patients was obtained from the MIMIC-IV database; these patients were predominantly elderly (median age 77.3 years) and male (55.6%). The XGBoost model effectively predicted 1-year mortality (Area under the curve (AUC): 0.833; 95% confidence intervals: 0.826-0.839), underscoring the significance of the Charlson Comorbidity Index (CCI) and the presence of metastatic solid tumors. The CRAMB score (Charlson comorbidity index, readmission, age, metastatic solid tumor, and blood urea nitrogen maximum) outperformed the CCI and CHA2DS2-VASc scores, demonstrating superior predictive value for 1-year mortality. In the test set, the area under the ROC curve (AUC) for the CRAMB score was 0.756 (95% confidence intervals: 0.748-0.764), surpassing the CCI score of 0.720 (95% confidence intervals: 0.712-0.728) and the CHA2DS2-VASc score of 0.609 (95% confidence intervals: 0.600-0.618). Decision curve analysis revealed that the CRAMB score had a consistently positive effect and greater net benefit across the entire threshold range than did the default strategies and other scoring systems. The calibration plot for the test set indicated that the CRAMB score was well calibrated. Conclusions This study’s primary contribution is the establishment of a benchmark for utilizing machine learning models in construction of a score for mortality prediction in AF. The CRAMB score was developed by leveraging a large-sample population dataset and employing XGBoost models for predictor screening. The simplicity of the CRAMB score makes it user friendly, allowing for coverage of a broader and more heterogeneous AF population.
12 May 2020 in Journal of Cardiovascular and Thoracic Research
In the study, we present the case of a 65-year-old male with rupture of right SVA into the right atrium that caused pleural effusion and acute right-sided heart failure (ARHF), which corrected by surgical intervention.